The Danish Generic and Biosimilars Medicines Industry Association (IGL) was founded as a trade association in 2002. Today, the association counts 12 member companies engaged in the production, marketing and sale of generic and biosimilar medicines on the Danish market. You can see a list of the current members here.
Until 2002, virtually all pharmaceutical companies in Denmark were members of the Danish Association of the Pharmaceutical Industry (Lif). However, the interests of the companies differed in several ways, primarily regarding patents and other terms and conditions with a direct impact on which medicines are sold in Denmark. The generics companies thus broke away from Lif to form IGL.
In 2015, it was decided to add “Biosimilars” to the name of IGL since these medicines has a growing importance on the Danish Market.